Tumor selective antivascular effects of the novel antimitotic compound ABT-751: An in vivo rat hemodynamic study

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 3, 2004, Pages 273-281

  Segreti, Jason A ^a   Polakowski, James S ^a   Koch, Kristin A ^a   Marsh, Kennan C ^a   Bauch, Joy L ^a   Rosenberg, Saul H ^a   Sham, Hing L ^a   Cox, Bryan F ^a   Reinhart, Glenn A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 751; Blood flow; In vivo; Rat; Tubulin; Tumor

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PHENYLEPHRINE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DRUG EFFECT; EPIGASTRIC ARTERY; EXPERIMENTAL MODEL; HEART RATE; HEMODYNAMICS; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE; VASOCONSTRICTION;

ABDOMINAL NEOPLASMS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; GLIOMA; HEMODYNAMIC PROCESSES; MALE; NEOPLASMS, EXPERIMENTAL; PYRIDONES; RATS; RATS, INBRED F344; SULFONAMIDES; TUBULIN; VASCULAR RESISTANCE;

EID: 4344647867     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482
2. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974
3. Buelke-Sam J, Holson JF, Bazare JJ, Young JF (1978) Comparative stability of physiological parameters during sustained anesthesia in rats. Lab Anim Sci 28:157
4. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80 [Suppl 1]:57
5. Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74 [Suppl XXVII]:S86
6. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MRL, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247
7. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafle N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408
8. Dredge K, Dalgleish AG, Marriott JB (2003) Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 4:667
9. Funahashi Y, Koyanagi N, Kitoh K (2001) Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine colon 38 tumor. Cancer Chemother Pharmacol 47:179
10. Gwaltney SL, Imade HM, Li Q, Gehrke L, Credo RB, Warner RB, Lee JY, Kovar P, Frost D, Ng SC, Sham HL (2001) Novel sulfonate derivatives: potent antimitotic agents. Bioorg Med Chem Lett 11:1671
11. Hande KR, Meek K, Lockhart AC, Glad-Anderson S, Berlin J, Eliopoulos H, Roth B, Roberts P, Rothenberg ML (2003) Pharmacokinetics and safety of ABT-751, a novel microtubulin inhibitor (abstract 520). Proc Am Soc Clin Oncol, vol. 22
12. Haywood JR, Schaffer RA, Fastenow C, Fink GD, Brody MJ (1981) Regional blood flow measurements with pulsed Doppler flowmeter in conscious rats. Am J Physiol 241:H273
13. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A:1320
14. Hill SA, Sampson LE, Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63:119
15. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N (1998) Preferential binding of E7010 to murine β-3 tubulin and decreased β3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 89:954
16. Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54:1702
17. Li Q, Sham HL (2002) Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Expert Opin Ther Patents 12:1663
18. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R (2003) Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63:1534
19. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789
20. Platts SH, Falcone JC, Holton WT, Hill MA, Meininger GA (1999) Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am J Physiol 277(1 Pt 2):H100
21. Rustin GJS, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815
22. Smits GJ, Perrone MH, Cox BF (1997) Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats. J Cardiovasc Pharmacol 29:49
23. Thorpe PE, Chaplin DJ, Blakey DC (2003) The first international conference on vascular targeting: meeting overview. Cancer Res 63:1144
24. Tozer GM, Shaffi KM, Prise VE, Cunningham VJ (1994) Characterisation of tumour blood flow using a "tissue-isolated" preparation. Br J Cancer 70:1040
25. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59:1626
26. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, Chaplin DJ (2001) Mechanisms associated: with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413
27. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K (1997) Mechanism of action of E7010, an orally active sulfonamide and tumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 57:3208
28. Yoshino H, Udea N, Niijima J, Sugumi H, Kotake Y, Koyanagi N, Yoshimatsu K, Asada M, Watanabe T, Nagasu T, Tsukahara K, Iijima A, Kitoh K (1992) Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 35:2496